![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2022
Zeyen, Thomas; Potthoff, Anna-Laura; Nemeth, Robert; Heiland, Dieter H.; Burger, Michael C.; Steinbach, Joachim P.; Hau, Peter; Tabatabai, Ghazaleh; Glas, Martin; Schlegel, Uwe; Grauer, Oliver; Krex, Dietmar; Schnell, Oliver; Goldbrunner, Roland; Sabel, Michael; Thon, Niklas; Delev, Daniel; Clusmann, Hans; Seidel, Clemens; Gueresir, Erdem; Schmid, Matthias; Schuss, Patrick; Giordano, Frank A.; Radbruch, Alexander; Becker, Albert; Weller, Johannes; Schaub, Christina; Vatter, Hartmut; Schilling, Judith; Winkler, Frank; Herrlinger, Ulrich und Schneider, Matthias
(2022):
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
In: Trials, Bd. 23, Nr. 1, 57
2020
Tzaridis, Theophilos; Schaefer, Niklas; Weller, Johannes; Steinbach, Joachim-Peter; Schlegel, Uwe; Seidel, Sabine; Sabel, Michael; Hau, Peter; Seidel, Clemens; Krex, Dietmar; Goldbrunner, Roland; Tonn, Jörg-Christian; Grauer, Oliver; Kebir, Sied; Schneider, Matthias; Schaub, Christina; Vatter, Hartmut; Coch, Christoph; Glas, Martin; Fimmers, Rolf; Pietsch, Torsten; Reifenberger, Guido; Herrlinger, Ulrich und Felsberg, Jörg
(2020):
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
In: International Journal of Cancer, Bd. 148, Nr. 7: S. 1695-1707
2019
Kebir, Sied; Schaub, Christina; Junold, Nina; Hattingen, Elke; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Galldiks, Norbert; Weller, Johannes; Mack, Frederic; Tzaridis, Theophilos; Baehr, Oliver; Seidel, Clemens; Schlegel, Uwe; Schmidt-Graf, Friederike; Rohde, Veit; Borchers, Christian; Tabatabai, Ghazaleh; Haenel, Mathias; Sabel, Michael; Gerlach, Rüdiger; Krex, Dietmar; Belka, Claus; Vatter, Hartmut; Proescholdt, Martin; Glas, Martin und Herrlinger, Ulrich
(2019):
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
In: Journal of Neuro-Oncology, Bd. 144, Nr. 3: S. 501-509
Herrlinger, Ulrich; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Sabel, Michael; Hau, Peter; Kortmann, Rolf-Dieter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Schnell, Oliver; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Kowalski, Thomas; Ringel, Florian; Schmidt-Graf, Friederike; Suchorska, Bogdana; Brehmer, Stefanie; Weyerbrock, Astrid; Renovanz, Miriam; Bullinger, Lars; Galldiks, Norbert; Vajkoczy, Peter; Misch, Martin; Vatter, Hartmut; Stuplich, Moritz; Schäfer, Niklas; Kebir, Sied; Weller, Johannes; Schaub, Christina; Stummer, Walter; Tonn, Jörg-Christian; Simon, Matthias; Keil, Vera C.; Nelles, Michael; Urbach, Horst; Coenen, Martin; Wick, Wolfgang; Weller, Michael; Fimmers, Rolf; Schmid, Matthias; Hattingen, Elke; Pietsch, Torsten; Coch, Christoph und Glas, Martin
(2019):
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
In: Lancet, Bd. 393, Nr. 10172: S. 678-688